Regen BioPharma Inc

Regen BioPharma Inc is a U.S.-based biopharmaceutical development company organized in Nevada and operating through its wholly owned subsidiary KCL Therapeutics, Inc. The company focuses on regenerative medical applications and early-stage drug candidates, including small molecules aimed at NR2F6 for oncology and autoimmune disease research.

−538,8 %

+0,0 %

0.04

0.04

— Regen BioPharma Inc
%
Regenerative medical applications40% Development-stage therapeutic applications intended for later-stage licensing or advancement.
Oncology programs30% Small-molecule and immune-activation candidates aimed at cancer applications.
Autoimmune disease programs20% Immune-cell suppression candidates designed for autoimmune indications.
Licensing and asset monetization10% Out-licensing or sale of developed applications after early clinical milestones.

Regen BioPharma does not appear to sell commercial products to a broad end-customer base; instead, its economic...

  • Pharmaceutical and biotechnology licenseesprimary

    Buy rights to early-stage therapeutic programs after proof-of-concept or early clinical work.

  • Strategic acquirersprimary

    Acquire developed applications or pipeline assets to add to their own portfolios.

  • Research collaboratorssecondary

    Support discovery and development work around NR2F6 and related immune pathways.

  • Financing counterpartiesprimary

    Provide debt or equity funding that enables ongoing development and corporate operations.

Regen BioPharma is headquartered in the United States and is organized under Nevada law, with office operations...

  • •United States is the core operating and corporate base
  • •Nevada is the state of incorporation
  • •California office space is used for administrative operations
  • •Clinical and regulatory activity is tied to U.S. FDA oversight
  • •No country-level revenue disclosure was provided

The company’s strategy is to identify and develop regenerative and immunology-related therapeutic candidates through...

01
Advance NR2F6-focused programsmedium-term

Clinical and scientific validation is needed before any licensing or sale value can be realized.

02
Monetize assets through partneringmedium-term

Licensing or sale can convert development work into value without building a commercial sales force.

03
Maintain access to financingshort-term

Development-stage biotech requires ongoing capital before product revenue is available.

Regen BioPharma faces the typical risks of an early-stage biotech company: clinical failure, regulatory delay, and...

critical

Going-concern and liquidity risk

The company states it may need additional equity or debt financing to support working capital and operations.

Scope
Corporate operations
Materiality
high
high

Clinical and regulatory failure

Therapeutic candidates are early-stage and must clear preclinical and FDA hurdles before value can be realized.

Scope
Pipeline programs
Materiality
high
high

Partnering and monetization risk

The business model depends on finding buyers or licensees for early-stage assets after development milestones.

Scope
Licensing strategy
Materiality
high
medium

Related-party concentration

Funding and facilities are tied to the CEO and related entities, increasing dependence on a small group of counterparties.

Scope
Financing and operations
Materiality
medium
Going concern
Affects asset/liability classification and investor assessment of solvency
Convertible notes and debt conversions
Can create noncash financing items and dilution
Related-party transactions
Important for transparency, valuation, and governance analysis
Research and development expense recognition
Drives reported losses before any product revenue exists

REGENERON PHARMACEUTICALS, INC.

REGN · Pharmaceutical Preparations

Vincerx Pharma, Inc.

Pharmaceutical Preparations

Generation Bio Co.

Pharmaceutical Preparations

REGENXBIO Inc.

RGNX · Biological Products, (No Diagnostic Substances)

REGENEREX PHARMA, INC.

Pharmaceutical Preparations

NEKTAR THERAPEUTICS

NKTR · Pharmaceutical Preparations

: 29/04/2026